» Articles » PMID: 24336327

SALL4 is a New Target in Endometrial Cancer

Overview
Journal Oncogene
Date 2013 Dec 17
PMID 24336327
Citations 58
Authors
Affiliations
Soon will be listed here.
Abstract

Aggressive cancers and embryonic stem (ES) cells share a common gene expression signature. Identifying the key factors/pathway(s) within this ES signature responsible for the aggressiveness of cancers can lead to a potential cure. In this study, we find that SALL4, a gene involved in the maintenance of ES cell self-renewal, is aberrantly expressed in 47.7% of primary human endometrial cancer samples. It is not expressed in normal or hyperplastic endometrial. More importantly, SALL4 expression is positively correlated with worse patient survival and aggressive features such as metastasis in endometrial carcinoma. Further functional studies have shown that loss of SALL4 inhibits endometrial cancer cell growth in vitro and tumorigenicity in vivo, as a result of inhibition of cell proliferation and increased apoptosis. In addition, downregulation of SALL4 significantly impedes the migration and invasion properties of endometrial cancer cells in vitro and their metastatic potential in vivo. Furthermore, manipulation of SALL4 expression can affect drug sensitivity of endometrial cancer cells to carboplatin. Moreover, we show that SALL4 specifically binds to the c-Myc promoter region in endometrial cancer cells. While downregulation of SALL4 leads to a decreased expression of c-Myc at both protein and mRNA levels, ectopic SALL4 overexpression causes increased c-Myc protein and mRNA expression, indicating that c-Myc is one of the SALL4 downstream targets in endometrial tumorigenesis. In summary, we are the first to demonstrate that SALL4 has functional role(s) in metastasis and drug resistance in aggressive endometrial cancer. As a consequence of its functional roles in cancer cell and absence in normal tissue, SALL4 is a potential novel therapeutic target for the high-risk endometrial cancer patient population.

Citing Articles

Enhanced Diagnostic Efficiency of Endometrial Carcinogenesis and Progression in Women with Abnormal Uterine Bleeding through Peripheral Blood Cytokine Testing: A Multicenter Retrospective Cohort Study.

Ma J, Liu D, Mao X, Huang L, Ren Y, Xu X Int J Med Sci. 2024; 21(4):601-611.

PMID: 38464838 PMC: 10920852. DOI: 10.7150/ijms.91506.


SALL4 promotes angiogenesis in gastric cancer by regulating VEGF expression and targeting SALL4/VEGF pathway inhibits cancer progression.

Abouelnazar F, Zhang X, Zhang J, Wang M, Yu D, Zang X Cancer Cell Int. 2023; 23(1):149.

PMID: 37525212 PMC: 10388482. DOI: 10.1186/s12935-023-02985-9.


The new advance of SALL4 in cancer: Function, regulation, and implication.

Abouelnazar F, Zhang X, Wang M, Zhang J, Yu D, Zang X J Clin Lab Anal. 2023; 37(9-10):e24927.

PMID: 37337914 PMC: 10388233. DOI: 10.1002/jcla.24927.


Dual-Regulated Mechanism of EZH2 and KDM6A on SALL4 Modulates Tumor Progression via Wnt/β-Catenin Pathway in Gastric Cancer.

Ren L, Deng H, Jiang Y, Liu C Dig Dis Sci. 2023; 68(4):1292-1305.

PMID: 36877334 DOI: 10.1007/s10620-022-07790-4.


Role of SALL4 in HER2+ Breast Cancer Progression: Regulating PI3K/AKT Pathway.

Pattanayak B, Lameirinhas A, Torres-Ruiz S, Burgues O, Rovira A, Martinez M Int J Mol Sci. 2022; 23(21).

PMID: 36362083 PMC: 9655635. DOI: 10.3390/ijms232113292.


References
1.
Elling U, Klasen C, Eisenberger T, Anlag K, Treier M . Murine inner cell mass-derived lineages depend on Sall4 function. Proc Natl Acad Sci U S A. 2006; 103(44):16319-24. PMC: 1637580. DOI: 10.1073/pnas.0607884103. View

2.
Frank S, Schroeder M, Fernandez P, Taubert S, Amati B . Binding of c-Myc to chromatin mediates mitogen-induced acetylation of histone H4 and gene activation. Genes Dev. 2001; 15(16):2069-82. PMC: 312758. DOI: 10.1101/gad.906601. View

3.
Kobayashi D, Kuribayashi K, Tanaka M, Watanabe N . Overexpression of SALL4 in lung cancer and its importance in cell proliferation. Oncol Rep. 2011; 26(4):965-70. DOI: 10.3892/or.2011.1374. View

4.
Saso S, Chatterjee J, Georgiou E, Ditri A, Smith J, Ghaem-Maghami S . Endometrial cancer. BMJ. 2011; 343:d3954. DOI: 10.1136/bmj.d3954. View

5.
Kobayashi D, Kuribayshi K, Tanaka M, Watanabe N . SALL4 is essential for cancer cell proliferation and is overexpressed at early clinical stages in breast cancer. Int J Oncol. 2011; 38(4):933-9. DOI: 10.3892/ijo.2011.929. View